Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Nov;57(11):1355–1359. doi: 10.1136/jnnp.57.11.1355

Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

M Emre 1, G C Leslie 1, C Muir 1, N J Part 1, R Pokorny 1, R C Roberts 1
PMCID: PMC1073186  PMID: 7964811

Abstract

In a double blind, placebo controlled, cross over study the correlations between single doses (2, 4, and 8 mg), plasma concentrations, and antispastic action of tizanidine were investigated in 16 patients with extensor spasticity of the legs due to multiple sclerosis. An electrogoniometer was used to assess muscle tone at knee extensors, applying Wartenberg's pendulum test. Blood samples, a clinical assessment of muscle tone by the Ashworth scale, and muscle strength by the British Medical Research Council scale were obtained concomitantly. Confirmatory analysis using the change in the relaxation index (R2 value) 1.5 hours after each treatment, showed a statistically significant (p = 0.0123) linear dose-response relation between single doses and antispastic action of tizanidine. Further statistical analysis showed a strong within patient linear correlation between plasma concentrations and antispastic action at 4 and 8 mg doses (p = 0.014 and 0.004 respectively), but only weak between patient correlations. The analysis of the dose-plasma concentration relation showed results consistent with linear pharmacokinetics. The comparison of changes in the R2 ratio with concomitant Ashworth scores showed a significant correlation between the two. It is concluded that there are linear correlations between single doses, plasma concentrations, and antispastic action of tizanidine. Because of the strong within patient but weak between patient correlation between plasma concentrations and antispastic action of tizanidine the effective doses should be determined individually.

Full text

PDF
1355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASHWORTH B. PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. Practitioner. 1964 Apr;192:540–542. [PubMed] [Google Scholar]
  2. Abt K. Descriptive data analysis: a concept between confirmatory and exploratory data analysis. Methods Inf Med. 1987 Apr;26(2):77–88. [PubMed] [Google Scholar]
  3. Bajd T., Vodovnik L. Pendulum testing of spasticity. J Biomed Eng. 1984 Jan;6(1):9–16. doi: 10.1016/0141-5425(84)90003-7. [DOI] [PubMed] [Google Scholar]
  4. Brown R. A., Lawson D. A., Leslie G. C., MacArthur A., MacLennan W. J., McMurdo M. E., Mutch W. J., Part N. J. Does the Wartenberg pendulum test differentiate quantitatively between spasticity and rigidity? A study in elderly stroke and Parkinsonian patients. J Neurol Neurosurg Psychiatry. 1988 Sep;51(9):1178–1186. doi: 10.1136/jnnp.51.9.1178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Curtis D. R., Leah J. D., Peet M. J. Spinal interneurone depression by DS103-282. Br J Pharmacol. 1983 May;79(1):9–11. doi: 10.1111/j.1476-5381.1983.tb10487.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davies J., Johnston S. E., Hill D. R., Quinlan J. E. Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at alpha 2-adrenoceptors. Neurosci Lett. 1984 Jul 27;48(2):197–202. doi: 10.1016/0304-3940(84)90019-3. [DOI] [PubMed] [Google Scholar]
  7. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282). Br J Pharmacol. 1982 Jul;76(3):473–481. doi: 10.1111/j.1476-5381.1982.tb09242.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eyssette M., Rohmer F., Serratrice G., Warter J. M., Boisson D. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin. 1988;10(10):699–708. doi: 10.1185/03007998809111121. [DOI] [PubMed] [Google Scholar]
  9. Hassan N., McLellan D. L. Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry. 1980 Dec;43(12):1132–1136. doi: 10.1136/jnnp.43.12.1132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hoogstraten M. C., van der Ploeg R. J., vd Burg W., Vreeling A., van Marle S., Minderhoud J. M. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand. 1988 Mar;77(3):224–230. doi: 10.1111/j.1600-0404.1988.tb05899.x. [DOI] [PubMed] [Google Scholar]
  11. Knutsson E., Mårtensson A., Gransberg L. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci. 1982 Feb;53(2):187–204. doi: 10.1016/0022-510x(82)90005-3. [DOI] [PubMed] [Google Scholar]
  12. Lapierre Y., Bouchard S., Tansey C., Gendron D., Barkas W. J., Francis G. S. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci. 1987 Aug;14(3 Suppl):513–517. doi: 10.1017/s0317167100038026. [DOI] [PubMed] [Google Scholar]
  13. Mathias C. J., Luckitt J., Desai P., Baker H., el Masri W., Frankel H. L. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev. 1989 Fall;26(4):9–16. [PubMed] [Google Scholar]
  14. Sayers A. C., Bürki H. R., Eichenberger E. The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent. Arzneimittelforschung. 1980;30(5):793–803. [PubMed] [Google Scholar]
  15. WARTENBERG R. Pendulousness of the legs as a diagnostic test. Neurology. 1951 Jan-Feb;1(1):18–24. doi: 10.1212/wnl.1.1.18. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES